Immunology follow-up after rituximab treatment in pediatric non Hodgkin lymfoma patients
Autoři | |
---|---|
Rok publikování | 2018 |
Druh | Konferenční abstrakty |
Fakulta / Pracoviště MU | |
Citace | |
Popis | Rituximab treatment leads to absolute transitional CD19+ B lymphocytopenia. IgG decrease could be delayed after the B cell recovery in the periphery. Clinical and laboratory sights of antibody secondary deficiency should be regularly monitored. |
Související projekty: |